GlobeStar Therapeutics Corporation

OTCPK:GSTC Stock Report

Market Cap: US$1.2k

GlobeStar Therapeutics Management

Management criteria checks 2/4

GlobeStar Therapeutics' CEO is Jim Katzaroff, appointed in Mar 2021, has a tenure of 5.17 years. directly owns 1.4% of the company’s shares, worth $17.42. The average tenure of the management team and the board of directors is 5.1 years and 5.1 years respectively.

Key information

Jim Katzaroff

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.2yrs
CEO ownership1.4%
Management average tenure5.1yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Katzaroff's remuneration changed compared to GlobeStar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$919k

Mar 31 2024n/an/a

-US$2m

Dec 31 2023n/an/a

-US$2m

Sep 30 2023US$233kn/a

-US$2m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

-US$783k

Dec 31 2022n/an/a

-US$1m

Sep 30 2022US$463kUS$178k

-US$1m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021n/an/a

-US$10m

Sep 30 2021US$2mUS$105k

-US$10m

Compensation vs Market: Insufficient data to establish whether Jim's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Jim's compensation with company performance.


CEO

Jim Katzaroff (68 yo)

5.2yrs
Tenure
US$233,117
Compensation

Mr. James C. Katzaroff, also known as Jim, serves as President, Chief Executive Officer and Director at GlobeStar Therapeutics Corporation since March 3, 2021 and serves as its Secretary, Principal Executi...


Leadership Team

NamePositionTenureCompensationOwnership
James Katzaroff
President5.2yrsUS$233.12k1.4%
$ 17.4
Brooke Greenwald
Chief Marketing Officer5.1yrsno datano data
David Croom
Executive Vice President5yrsno datano data
5.1yrs
Average Tenure

Experienced Management: GSTC's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Katzaroff
President5.2yrsUS$233.12k1.4%
$ 17.4
William Farley
Director5.1yrsno datano data
Steven Penderghast
Director5.1yrsno datano data
Leonard Wisneski
Chairman of Medical Advisory Board5yrsno datano data
5.1yrs
Average Tenure

Experienced Board: GSTC's board of directors are considered experienced (5.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 17:06
End of Day Share Price 2026/05/07 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GlobeStar Therapeutics Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.